课题基金 / 基金详情

Cytokines in Glial Cells and EAE Brain

Cytokines in Glial Cells and EAE Brain
神经胶质细胞和 EAE 脑中的细胞因子
批准号:
8403518
负责人:
Inderjit Singh
金额:
$30.51万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2014-11-30
关键词:
AffectAgonistAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAttenuatedAutoimmune ProcessBlood - brain barrier anatomyBrainBrain-Derived Neurotrophic FactorCD4 Positive T LymphocytesCell Culture SystemCellsCentral Nervous System DiseasesCholesterolChronicCiliary Neurotrophic FactorComplementCopaxoneDemyelinating DiseasesDemyelinationsDevelopmentDiseaseDisease modelDrug TargetingEventExperimental Autoimmune EncephalomyelitisFamilyFarnesyl Transferase InhibitorGlial Growth FactorGuanosine Triphosphate PhosphohydrolasesHelper-Inducer T-LymphocyteHomeostasisImmuneImmune responseImmunosuppressionIn VitroIndividualInflammatoryInsulin-Like Growth Factor IInterferonsInterleukinsLIF geneLaboratoriesLesionLipidsLovastatinLow Density Lipoprotein ReceptorMaintenanceMediatingModelingMonomeric GTP-Binding ProteinsMultiple SclerosisMultiple Sclerosis LesionsMyelinMyelin Associated GlycoproteinMyelin Basic ProteinsMyelin ProteinsNRG1 geneNecrosisNerve DegenerationNeuraxisNeurodegenerative DisordersNeurogliaNeurologicNeuronsOligodendrogliaPGGT1B genePTEN genePTGS2 genePatientsPeroxisome Proliferator-Activated ReceptorsPharmaceutical PreparationsPhospholipasePhosphoric Monoester HydrolasesPlatelet-Derived Growth FactorPolymerase Chain ReactionPropertyProteinsProteolipidsReceptor ActivationRegulationRelapseReportingReverse Transcriptase Polymerase Chain ReactionRho-associated kinaseSignal PathwaySignal TransductionSpinal CordTNF geneTestingTherapeuticTimeTreatment EfficacyTumor Suppressionarmbasebrain-derived growth factorcentral nervous system demyelinating disordercentral nervous system injurycyclooxygenase 2cytokinedesigndisabilitydrug candidateeffective therapyfarnesyl pyrophosphategeranylgeranyl pyrophosphateglycerone-phosphate O-acyltransferaseimprovedinhibitor/antagonistinnovationisoprenoidleukemiamevalonatemouse modelmyelin degenerationneuroprotectionnew therapeutic targetnoveloligodendrocyte-myelin glycoproteinopen labelprecursor cellprogenitorprotein geranylgeranyltransferasepublic health relevanceremyelinationrepairedrhotensintherapeutic targettumor

项目摘要

项目成果

Inderjit Singh的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Multiple Sclerosis (MS), an inflammatory demyelinating disease, lacks effective treatment because the current MS drugs targeting immunosuppression provide limited, if any, benefit to the central nervous system (CNS) disease where it continues to progress. This proposal is designed to investigate the potential of drugs targeting the Rho family GTPases (RFGs) for induction of endogenous myelin repair mechanisms in the CNS of EAE/MS. Previous studies from our laboratory and others have demonstrated that isoprenoids mediated regulation of RFGs with statins provides immunomodulatory and blood-brain-barrier protection activities in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Our recent studies provide evidence for involvement of RFGs mediated mechanisms in neuroprotection as revealed by reduced demyelination (loss of both myelin proteins and lipids) and loss of OL-progenitors in EAE. Moreover, in vitro studies with mixed glial cultures document that RFGs mediated mechanisms may also potentially provide promyelinating effects as evidenced by enhanced survival and differentiation of oligodendrocyte (OL)-progenitors. Importantly, these effects of statins were attributed to be the specific depletion of intracellular isoprenoids rather than the level of cholesterol in the cells or CNS. Moreover, the observed reduced levels of peroxisome proliferator activated receptors (PPARs) in the CNS of EAE and their normalization and activation by statin indicates that statin-RFGs mediated mechanisms may regulate the cellular homeostasis of PPARs. Based on this information, we hypothesize that statin mediated regulation of RFGs may modulate PPARs activities in OL-progenitors to promote their differentiation into remyelinating OLs in the CNS of EAE animals. The following studies are proposed to test this hypothesis. Specific aim 1: To investigate the RFGs mediated regulatory mechanisms for PPARs activation for the survival and differentiation of OL-progenitors in vitro cell culture systems. Specific aim 2: To evaluate the significance of RFGs induced PPARs activities in the induction of myelin repair in the inflammatory demyelinating model of EAE. The novelty of the study is to identify new therapeutic targets for induction of myelin repair for improved treatment and management of neurodegenerative diseases such as MS. Therapeutic targeting of neural cell mechanisms in inflammatory demyelinating model is essentially an innovative approach.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neurorestorative Therapy for Stroke Injury
Neurorestorative Therapy for Stroke Injury
Immunomodulation and Neuroprotection in Multiple Sclerosis
Immunomodulation and Neuroprotection in Multiple Sclerosis
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: